Ekkehard Schütz

Chief Tech/Sci/R&D Officer at ONCOCYTE CORPORATION

Net worth: - $ as of 2024-04-29

Health Technology

Consumer Services

Profile

Ekkehard Schütz is currently the Chief Executive Officer & Chief Medical Officer at Chronix Biomedical, Inc. He is also the Managing Director at Chronix Biomedical GmbH since 2011.
Additionally, he holds the position of Chief Science Officer at OncoCyte Corp.
starting from 2021.
Dr. Schütz obtained his doctorate degree from the University of Gottingen.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
ONCOCYTE CORPORATION -.--%	2024-04-28	0 ( -.--% )	- $	2024-04-29

Ekkehard Schütz active positions

Companies	Position	Start
ONCOCYTE CORPORATION	Chief Tech/Sci/R&D Officer	2021-03-31
Chronix Biomedical, Inc. Chronix Biomedical, Inc. Medical SpecialtiesHealth Technology Chronix Biomedical, Inc. manufactures diagnostic substances chemicals. It develops DNA-based blood tests primarily for monitoring minimal residual disease in cancer patients. The firm also develops a technology that measures personalized biomarkers in cancers of the colorectum, prostate, lung, ovarian, pancreas, blood and central nervous system. The company was founded by Wiiliam A. Boeger and Howard B. Urnovitz in 1997 and is headquartered in San Jose, CA.	Chief Executive Officer	-
Chronix Biomedical GmbH	Corporate Officer/Principal	2011-03-31

All active positions of Ekkehard Schütz

Training of Ekkehard Schütz

University of Gottingen

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Ekkehard Schütz's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
ONCOCYTE CORPORATION	Health Technology

Private companies	2
Chronix Biomedical, Inc. Chronix Biomedical, Inc. Medical SpecialtiesHealth Technology Chronix Biomedical, Inc. manufactures diagnostic substances chemicals. It develops DNA-based blood tests primarily for monitoring minimal residual disease in cancer patients. The firm also develops a technology that measures personalized biomarkers in cancers of the colorectum, prostate, lung, ovarian, pancreas, blood and central nervous system. The company was founded by Wiiliam A. Boeger and Howard B. Urnovitz in 1997 and is headquartered in San Jose, CA.	Health Technology
Chronix Biomedical GmbH